A Randomized Phase II Study to Evaluate Efficacy of T-DM1 With or Without Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer

What is the purpose of this trial?

This is a randomized phase II study to evaluate if the combination of T-DM1 with palbociclib improves progression-free survival compared to single agent T-DM1in patients with metastatic HER2 positive breast cancer



University of Arizona Cancer Center

Start Date: 01/22/2019

End Date: 09/01/2019

Last Updated: 01/24/2019

Study HIC#: 2000023405

Get Involved

For more information about this study, contact:
Trisha Burrello
+1 203-737-2848
trisha.burrello@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image